Pharmacoepidemiol Drug Saf 2020 06 22;29(6):684-691. Epub 2020 Apr 22.
Division of Pharmacovigilance, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, Silver Spring, Maryland, USA.
Purpose: To identify and analyze postmarketing cases of complex sleep behaviors (CSBs) resulting in serious injuries, including death, associated with eszopiclone, zaleplon, or zolpidem (Z-drugs).
Methods: Retrospective analysis of the U.S. Read More